The authors declare no conflict of interest.
State of the Art Review
A review of the pharmacology and clinical uses of pimobendan.
Article first published online: 28 AUG 2012
© Veterinary Emergency and Critical Care Society 2012
Journal of Veterinary Emergency and Critical Care
Volume 22, Issue 4, pages 398–408, August 2012
How to Cite
Boyle, K. L. and Leech, E. (2012), A review of the pharmacology and clinical uses of pimobendan. Journal of Veterinary Emergency and Critical Care, 22: 398–408. doi: 10.1111/j.1476-4431.2012.00768.x
- Issue published online: 28 AUG 2012
- Article first published online: 28 AUG 2012
- Manuscript Accepted: 9 MAY 2012
- Manuscript Received: 31 OCT 2010
- cardiotonic agents;
- phosphodiesterase inhibitors;
- vasodilator agents
To review the pharmacology, research developments, and clinical uses of pimobendan
Original research articles and clinical studies from 1984 to August 2011.
Veterinary Data Synthesis
Pimobendan is approved for use in dogs for the treatment of congestive heart failure (CHF) secondary to chronic valvular heart disease (CVHD) and dilated cardiomyopathy (DCM). Expert-based veterinary guidelines recommend the use of pimobendan in the management of acute, hospital-based therapy for patients with CHF attributable to CVHD.
The use of pimobendan, an inodilator with phosphodiesterase 3 (PDE3) inhibitory and calcium-sensitizing properties, is regarded as a component of the standard of care in the management of dogs with CHF secondary to both DCM and CVHD. Further studies are warranted to confirm the safety and efficacy of pimobendan for the off-label use of this drug in asymptomatic CVHD, pulmonary arterial hypertension, asymptomatic myocardial diseases, CHF from all other causes and in cats with CHF.